Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience
Myeloma patients are at an increased risk of severe forms of Covid-19. We examined response to mRNA vaccine between myeloma patients (n.127) and healthy volunteers (n.50). Anti-spike IgG antibody were detected in 76.9% of evaluable patients. 23.1% of MM patients failed to respond at two doses of COV...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048922000541 |
| _version_ | 1811201698764423168 |
|---|---|
| author | Mele Giuseppe Romano Claudia Miccoli Antonella Santoro Angelo Pastore Domenico |
| author_facet | Mele Giuseppe Romano Claudia Miccoli Antonella Santoro Angelo Pastore Domenico |
| author_sort | Mele Giuseppe |
| collection | DOAJ |
| description | Myeloma patients are at an increased risk of severe forms of Covid-19. We examined response to mRNA vaccine between myeloma patients (n.127) and healthy volunteers (n.50). Anti-spike IgG antibody were detected in 76.9% of evaluable patients. 23.1% of MM patients failed to respond at two doses of COVID-19 mRNA vaccine. Univariate analyses identified three independent adverse predictive factors of absence of immunological response to COVID-19 vaccine: extreme plasmacytosis (p < 0.001), B2M (p 0.006), and haemoglobin (p 0.008). Multivariate analysis confirmed the extreme plasmacytosis and haemoglobin value as statistically significant variables. |
| first_indexed | 2024-04-12T02:26:07Z |
| format | Article |
| id | doaj.art-d87e9e478a294e9192863f4361802b30 |
| institution | Directory Open Access Journal |
| issn | 2213-0489 |
| language | English |
| last_indexed | 2024-04-12T02:26:07Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj.art-d87e9e478a294e9192863f4361802b302022-12-22T03:52:00ZengElsevierLeukemia Research Reports2213-04892022-01-0118100342Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experienceMele Giuseppe0Romano Claudia1Miccoli Antonella2Santoro Angelo3Pastore Domenico4Haematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi, Italy; Corresponding author.Haematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi, ItalyBlood and Transfusion Medicine Department, Ospedale Antonio Perrino, Brindisi, ItalyLaboratory Medicine Department, Ospedale Antonio Perrino, Brindisi, ItalyHaematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi, ItalyMyeloma patients are at an increased risk of severe forms of Covid-19. We examined response to mRNA vaccine between myeloma patients (n.127) and healthy volunteers (n.50). Anti-spike IgG antibody were detected in 76.9% of evaluable patients. 23.1% of MM patients failed to respond at two doses of COVID-19 mRNA vaccine. Univariate analyses identified three independent adverse predictive factors of absence of immunological response to COVID-19 vaccine: extreme plasmacytosis (p < 0.001), B2M (p 0.006), and haemoglobin (p 0.008). Multivariate analysis confirmed the extreme plasmacytosis and haemoglobin value as statistically significant variables.http://www.sciencedirect.com/science/article/pii/S2213048922000541Symptomatic multiple myelomaCOVID-19 mRNA vaccine |
| spellingShingle | Mele Giuseppe Romano Claudia Miccoli Antonella Santoro Angelo Pastore Domenico Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience Leukemia Research Reports Symptomatic multiple myeloma COVID-19 mRNA vaccine |
| title | Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience |
| title_full | Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience |
| title_fullStr | Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience |
| title_full_unstemmed | Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience |
| title_short | Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience |
| title_sort | long follow up of symptomatic multiple myeloma patients after covid 19 vaccination bnt162b2 a single institution retrospective experience |
| topic | Symptomatic multiple myeloma COVID-19 mRNA vaccine |
| url | http://www.sciencedirect.com/science/article/pii/S2213048922000541 |
| work_keys_str_mv | AT melegiuseppe longfollowupofsymptomaticmultiplemyelomapatientsaftercovid19vaccinationbnt162b2asingleinstitutionretrospectiveexperience AT romanoclaudia longfollowupofsymptomaticmultiplemyelomapatientsaftercovid19vaccinationbnt162b2asingleinstitutionretrospectiveexperience AT miccoliantonella longfollowupofsymptomaticmultiplemyelomapatientsaftercovid19vaccinationbnt162b2asingleinstitutionretrospectiveexperience AT santoroangelo longfollowupofsymptomaticmultiplemyelomapatientsaftercovid19vaccinationbnt162b2asingleinstitutionretrospectiveexperience AT pastoredomenico longfollowupofsymptomaticmultiplemyelomapatientsaftercovid19vaccinationbnt162b2asingleinstitutionretrospectiveexperience |